Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-106389
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women
Bedeutung der Ovarialsuppression in der endokrinen Therapie des Mammakarzinoms der prämenopausalen FrauPublication History
received 04 January 2016
revised 11 April 2016
accepted 11 April 2016
Publication Date:
19 May 2016 (online)
![](https://www.thieme-connect.de/media/gebfra/201605/lookinside/thumbnails/10-1055-s-0042-106389_gf1061-1.jpg)
Abstract
Ovarian function suppression (OFS) for treating breast cancer in pre-menopausal women was introduced for the first time in the late 19th century as bilateral oophorectomy. It was not until the 1960s that the oestrogen receptor was identified and a test for detecting endocrine sensitivity of the breast cancer was developed. A weakness of early trials on OFS for breast cancer treatment is therefore their failure to take receptor sensitivity into account when selecting participants. A meta-analysis performed in the early 1990s first proved that adjuvant OFS significantly improved the cure rate of oestrogen receptor-positive breast cancer in pre-menopausal women regardless of whether it was carried out through oophorectomy, radiation-induced ablation or drug therapy. In the 1970s, tamoxifen was synthesized. It became one of the most important cancer drugs and today constitutes the gold standard for endocrine adjuvant therapy. Taking tamoxifen for a five-year period lowers mortality by 30 % over 15 years. Ten years of tamoxifen therapy reduces mortality even further, with increased side effects, however. Research over the past ten years has proven that for post-menopausal women, aromatase inhibitors have benefits over tamoxifen. Current trial results have rekindled the debate about the combination of OFS with tamoxifen or with aromatase inhibitors for adjuvant breast cancer treatment of pre-menopausal women. These trials have reported an improvement in disease-free survival in patients with a high risk of recurrence when they are treated with a combination of OFS plus tamoxifen or aromatase inhibitors, especially in women younger than 35. However, combination therapy causes significantly more side effects, which could negatively impact compliance. Endocrine treatments administered over a period of many years show waning compliance, which tends to be only around 50 % after five years. Inadequate compliance compromises efficacy and increases the risk of mortality. For this reason, when indicating and supporting endocrine adjuvant therapy, physicians must ensure that compliance will be good. To prevent recurrence in the long run, it is much more effective to prescribe a somewhat less effective therapy that will actually be carried out than to prescribe one that is theoretically more effective, but is not adhered to consistently.
Zusammenfassung
Die Ovarialsuppression als Therapie des Mammakarzinoms der prämenopausalen Frau wurde erstmals Ende des 19. Jahrhunderts als bilaterale Ovarektomie durchgeführt. Erst in den 1960er-Jahren wurde der Östrogenrezeptor identifiziert und ein Test zum Nachweis der endokrinen Sensitivität des Mammakarzinoms entwickelt. Die frühen Studien zur OFS beim Mammakarzinom leiden daher darunter, dass keine Selektion nach Rezeptorpositivität des Tumors erfolgte. Erst eine Metaanalyse Anfang der 1990er-Jahre konnte nachweisen, dass die adjuvante Ovarialsuppression zu einer deutlichen Verbesserung der Heilungsrate des rezeptorpositiven Mammakarzinoms der prämenopausalen Frau führt, unabhängig davon, ob sie durch Ovarektomie, Radiokastration oder medikamentös erfolgt. In den 1970er-Jahren wurde Tamoxifen synthetisiert. Durch glückliche Zufälle wurde es zu einem der wichtigsten onkologischen Medikamente und ist heute der Goldstandard der endokrinen adjuvanten Therapie. Eine 5-jährige Einnahme senkt die Mortalität über 15 Jahre um 30 %; die 10-jährige Tamoxifentherapie ermöglicht eine zusätzliche Mortalitätssenkung allerdings bei Zunahme der Nebenwirkungen. Für postmenopausale Frauen wurde im letzten Jahrzehnt nachgewiesen, dass Aromatasehemmer gegenüber Tamoxifen Vorteile aufweisen. Aktuelle Studienergebnisse entfachten die Diskussion über die Kombination von Ovarialsuppression mit Tamoxifen oder mit Aromatasehemmern zur adjuvanten Therapie prämenopausaler Patientinnen neu. Sie hatten eine Verbesserung des krankheitsfreien Überlebens bei Patientinnen mit hohem Rezidivrisiko durch Kombination von Ovarialsuppression mit Tamoxifen oder Aromatasehemmern v. a. bei Frauen unter 35 Jahren gezeigt. Allerdings hat die Kombinationstherapie deutlich mehr Nebenwirkungen, was die Compliance negativ beeinflussen könnte. Die jahrelangen endokrinen Therapien leiden unter einer abnehmenden Compliance, die nach 5 Jahren in der Regel nur noch bei 50 % liegt. Eine unzureichende Compliance vermindert den Effekt und erhöht das Mortalitätsrisiko. Daher muss bei der Indikationsstellung und Begleitung der endokrinen adjuvanten Therapie auf eine gute Compliance geachtet werden. Eine tatsächlich durchgeführte Therapie, mit evtl. etwas geringerer Wirkung kann onkologisch sinnvoller sein als eine prinzipiell wirksamere Behandlung, die aber nicht konsequent durchgeführt wird.
Key words
pre-menopause - breast cancer - compliance - ovarian function suppression - tamoxifen - aromatase inhibitorsSchlüsselwörter
Prämenopause - Mammakarzinom - Compliance - Ovarialsuppression - Tamoxifen - Aromatasehemmer-
References
- 1 Scharl A, Salterberg A. Multimodale Therapie des nicht metastasierten Mammakarzinoms. Onkologe 2014; 4: 379-394
- 2 Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002; 94: 1433-1434
- 3 Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-320
- 4 Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118
- 5 Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446
- 6 Scharl A, Kühn T, Papathemelis T et al. The right treatment for the right patient – personalised treatment of breast cancer. Geburtsh Frauenheilk 2015; 75: 683-691
- 7 Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147 (Suppl. 01) S269-S276
- 8 Scharl A, Vierbuchen M, Würz H. Immunhistochemischer Nachweis von Östrogen- und Progesteronrezeptoren beim Mammakarzinom mit Hilfe monoklonaler Antikörper: Vergleich mit der biochemischen Rezeptoranalyse. Pathologe 1989; 10: 31-38
- 9 Early Breast Cancer Trialistsʼ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15 71–85
- 10 Early Breast Cancer Trialistsʼ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
- 11 Goel S, Sharma R, Hamilton A et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009; (4) CD004562
- 12 Pritchard K. Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. Breast Cancer Res 2005; 7: 70-76
- 13 Jakesz R, Hausmaninger H, Kubista E et al. Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002; 20: 4621-4627
- 14 Kaufmann M, Jonat W, Blamey R et al. Zoladex Early Breast Cancer Research Association (ZEBRA) Trialistsʼ Group. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003; 39: 1711-1717
- 15 Ejlertsen B, Mouridsen HT, Jensen MB et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006; 24: 4956-4962
- 16 Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769-5779
- 17 Swain SM, Jeong JH, Geyer jr. CE et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065
- 18 International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332-1341
- 19 Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784
- 20 Davies C, Pan H, Godwin J et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816
- 21 Gray RG, Rea D, Handley K et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (Suppl.) Abstr. 5
- 22 Delozier T, Switsers O, Genot JY et al. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (tam-02 trial). Ann Oncol 2000; 11: 515-519
- 23 Söreide JA, Varhaug JE, Fjösne HE et al. Adjuvant endocrine treatment (goserelin vs. tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol 2002; 28: 505-510
- 24 Diamond MP, Legro RS, Coutifaris C et al. NICHD Reproductive Medicine Network. Letrozole, gonadotropin, or clomiphene for unexplained infertility. N Engl J Med 2015; 373: 1230-1240
- 25 Dowsett M, Forbes JF, Bradley R et al. Early Breast Cancer Trialistsʼ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341-1352
- 26 Goss PE, Ingle JN, Pritchard KI et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol 2013; 31: 1398-1404
- 27 OʼShaughnessy J, Yardley DA, Burris HA et al. Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial. San Antonio Breast Cancer Symposium 2015; Abstr. PD2-01.
- 28 Davidson NE, OʼNeill AM, Vukov AM et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005; 23: 5973-5982
- 29 Cuzick J, Ambroisine L, Davidson N et al. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711-1723
- 30 Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126: 529-537
- 31 Cuzick J, Sestak I, Forbes JF et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 383: 1041-1048
- 32 Hadji P, Ziller V, Kyvernitakis J et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat 2013; 138: 185-191
- 33 Kidwell KM, Harte SE, Hayes DF et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 2014; 120: 2403-2411
- 34 Fellowes D, Fallowfield LJ, Saunders CM et al. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?. Breast Cancer Res Treat 2001; 66: 73-81
- 35 Kommission Mamma der AGO. Adjuvant endocrine therapy in pre- and postmenopausal patients. Online: http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/Maerz2016/en/2016E%252010_Adjuvant%2520Endocrine%2520Therapy%2520in%2520Pre-%2520and%2520ostmenopausal%2520%2520Patients.pdf last access: 04.04.2016